Bausch + Lomb acquires Elios Vision
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a global eye health company, has announced that an affiliate has acquired Elios Vision, Inc., developer of the ELIOS procedure, a clinically validated, minimally invasive glaucoma surgery (MIGS) procedure. According to Bausch + Lomb, the acquisition offers opportunities to treat glaucoma effectively in conjunction with cataract surgery without implants while bolstering the company’s glaucoma portfolio. “Today’s announcement further demonstrates our commitment to investing in smart, innovative technologies that enable eyecare professionals to better address the evolving needs of their patients,” said Luc Bonnefoy, president, Surgical, Bausch + Lomb. “The ELIOS system offers a differentiated approach for the treatment of glaucoma, a condition expected to increase in prevalence by 47 percent from 2020 to 2040.”
Compared to other glaucoma surgery techniques, MIGS offers a safe and effective approach to lowering intraocular pressure with faster recovery time. It can also often be performed in conjunction with cataract surgery, according to the announcement.
“ELIOS provides a tissue-friendly, precision non-thermal laser-based and highly adoptable procedure for the treatment of glaucoma,” said professor Ike K. Ahmed, MD, University of Toronto and Moran Eye Center. “The synergy between cataract surgery and MIGS can help ophthalmologists provide streamlined care and improve patients’ quality of life.”
The ELIOS technology, which is CE marked, is currently marketed and sold in the European Union. Elios Vision is in the process of pursuing U.S. Food and Drug Administration approval for the product.
“Bausch + Lomb’s extensive reach in cataract surgery will introduce ELIOS to a broader range of eyecare professionals and help change the treatment paradigm for the estimated 80 million people worldwide living with glaucoma,” said Elliot Friedman, former Elios Vision chairman and CEO. “The goal is to make combining cataract and glaucoma treatment the new standard of care, and that’s even more attainable given Bausch + Lomb’s presence in nearly 100 countries.”
